Why Is Dihydroergotamine So Hard to Find? [Explained for 2026]

If you rely on Dihydroergotamine — commonly known as DHE — to treat your migraines, you may have recently walked into a pharmacy only to hear those dreaded words: "We don't have it in stock." You're not alone. Across the country, patients are struggling to fill their prescriptions for this critical migraine medication.

In this article, we'll explain what Dihydroergotamine is, why it's so hard to find in 2026, and — most importantly — what steps you can take to get the medication you need.

What Is Dihydroergotamine?

Dihydroergotamine Mesylate (DHE) is an ergot alkaloid medication used to treat acute migraine attacks and cluster headaches. It works by narrowing dilated blood vessels in the brain and blocking the release of inflammatory substances that cause migraine pain. Unlike preventive medications, DHE is taken at the onset of a migraine to stop the attack in its tracks.

DHE has been used for decades and is available in several forms: an injectable solution (previously sold as D.H.E. 45), a nasal spray (Migranal), a newer nasal spray using POD technology (Trudhesa), a nasal powder (Atzumi), and a subcutaneous autoinjector (Brekiya). It's often prescribed when triptans like Sumatriptan don't work well enough or aren't an option.

Why Is Dihydroergotamine So Hard to Find?

There isn't just one reason DHE is hard to find. Several factors are working together to create a perfect storm of limited supply:

1. Very Few Manufacturers

The original brand-name injectable, D.H.E. 45, was discontinued years ago. Today, Hikma Pharmaceuticals is the primary manufacturer of the generic injectable form. When you have just one or two companies making a drug, any production hiccup — maintenance shutdowns, raw material delays, quality control issues — can lead to widespread shortages.

2. Complex Manufacturing Process

Ergot alkaloids like Dihydroergotamine are derived from complex chemical processes. Unlike simpler generic drugs, manufacturing DHE requires specialized equipment and strict quality controls. This complexity limits the number of facilities that can produce it and makes scaling up production difficult.

3. Increased Demand

As awareness of DHE's effectiveness has grown — especially for patients who don't respond well to triptans — demand has increased. Headache specialists and emergency departments rely heavily on DHE infusions for status migrainosus (migraines lasting more than 72 hours) and medication overuse headache protocols. This puts additional pressure on an already limited supply.

4. High Cost of Brand-Name Alternatives

While newer formulations like Trudhesa (nasal spray), Brekiya (autoinjector), and Atzumi (nasal powder) have expanded the options for DHE delivery, they come at a steep price. Trudhesa can cost over $4,000 without insurance. These high price tags mean many patients are funneled back toward the lower-cost generic injectable, intensifying the demand on an already constrained supply.

What You Can Do

If you're having trouble finding Dihydroergotamine, here are some practical steps you can take right now:

• Use Medfinder — Medfinder.com helps you check which pharmacies near you currently have Dihydroergotamine in stock, saving you hours of phone calls.
• Try independent pharmacies — Smaller, independent pharmacies often have access to different wholesalers and distributors than the big chains. They may have stock when CVS or Walgreens doesn't.
• Ask about alternative formulations — If the injectable is out of stock, ask your doctor about Trudhesa, Brekiya, or Atzumi. While pricier, manufacturer savings programs may bring your cost down significantly.
• Discuss alternatives with your provider — Medications like Sumatriptan, Lasmiditan (Reyvow), or Ubrogepant (Ubrelvy) may be appropriate alternatives. Read more in our guide to Dihydroergotamine alternatives.
• Plan ahead — Don't wait until you're out. Try to refill your prescription a week before you run out. If your pharmacy allows, ask them to place a special order from their wholesaler.

What About the Newer DHE Products?

In 2025, two new Dihydroergotamine products were approved by the FDA: Brekiya (a subcutaneous autoinjector) and Atzumi (a nasal powder). These join Trudhesa (approved in 2021) as alternatives to the traditional injectable and Migranal nasal spray.

These newer products are designed for easier at-home use — no need for IV infusions in a clinic. However, they tend to be more expensive and may require prior authorization from your insurance company. If you're interested, ask your neurologist or headache specialist whether one of these newer formulations might be right for you.

Final Thoughts

Dihydroergotamine is hard to find in 2026 because of a combination of limited manufacturers, complex production, rising demand, and the high cost of brand-name alternatives that pushes patients toward the generic. It's a frustrating situation, especially when you're in the middle of a migraine attack and need relief fast.

The good news is that tools like Medfinder can help you locate pharmacies with Dihydroergotamine in stock, and new formulations are expanding the options available to patients. Don't give up — work with your provider to find the best path forward for your treatment.